ArticleCureus2026
Immediate Glycemic Outcomes Following Simultaneous Pancreas-Kidney Transplantation: Equivalent Early Metabolic Profiles in Type 1 and Type 2 Diabetes.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveSimultaneous pancreas-kidney transplantation (SPKT) is increasingly performed in both type 1 and carefully selected type 2 diabetes mellitus recipients. Although long-term outcomes are well described, early postoperative glycemic behavior remains poorly defined. Persistent hyperglycemia during the early postoperative phase raises concerns regarding potential technical complications or acute rejection after SPKT. In contrast, early normalization of glucose levels suggests pancreas graft viability and sufficient functional beta-cell mass. Despite extensive long-term data, comparative evidence between T1DM and T2DM recipients is limited. This study compares early glycemic trajectories, perioperative glycemic management, and short-term outcomes between these groups.
methodsWe conducted a single-center retrospective study of adult SPKT recipients from January 2018 to December 2025. Exclusion criteria were multiorgan transplantation beyond SPKT, pancreas graft loss or patient death within 24 hours, and incomplete early postoperative glucose data. Perioperative glucose interventions, pancreatic enzyme markers, and glucose values obtained at predefined postoperative time points (6, 12, and 24 hours; POD 7, 14, and 28) were analyzed. Primary outcomes included early glucose levels and insulin independence at one month, a clinically meaningful indicator of endocrine graft function. Secondary outcomes included delayed graft function, postoperative complications, return to the operating room, pancreatic enzyme levels, and length of hospital stay.
resultsAmong 80 SPKT recipients, 31 (38.8%) had T1DM and 49 (61.2%) had T2DM. T2DM recipients were older (50.3 ± 9.3 vs. 41.3 ± 9.3 years, p = 0.001) and had a higher body mass index (27.0 ± 3.5 vs. 24.9 ± 4.0 kg/m², p = 0.016). T1DM recipients, in contrast, had a longer duration of diabetes and lower C-peptide levels (both
conclusionsEarly postoperative glycemic control and short-term graft outcomes are comparable between type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) SPKT recipients, supporting the safety and applicability of standardized perioperative glycemic protocols across both populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.